Steering Committee (2026)

The ASGH Steering Committee acts as the advisory body to provide guidance on planning and preparation of the Summit. Formed by experienced professionals representing Hong Kong’s biotech, healthcare and finance sectors, the Steering Committee advises on both strategic and operational issues of ASGH.

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Assistant Executive Director</div>The Hong Kong Trade Development Council

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2026/02/Anna_Cheung.jpg" /></div><div><div class="speaker-name">Ms Anna Cheung</div><div class="speaker-company">Assistant Executive Director</div><div class="speaker-title">The Hong Kong Trade Development Council</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Ms Anna Cheung is the Assistant Executive Director of the Hong Kong Trade Development Council (HKTDC), the statutory organisation dedicated to promoting Hong Kong’s trade. She oversees the Council’s international and mainland activities that promote Hong Kong’s service industries, merchandise trade, and innovation and technology.<br><br>Ms Cheung joined the Council as an Executive Trainee in 1997. From 2000 to 2002, she was posted to the Council’s branch office in Milan, spearheading the Council’s promotional programmes in Italy and promoting Hong Kong as a trading partner of Italy. As Associate Director from 2010-2019, she has held various positions in the Council including serving the Exhibitions division, where she managed the special events, project planning and operation of over 30 annual fairs. Her work also extended to overseeing the promotion of creative industries, ICT, as well as logistics and infrastructure related services.<br><br>In 2020, Ms Cheung was appointed as Director, Service Promotion, overseeing the promotion strategies and activities related to Hong Kong’s service industries and the Belt and Road Initiatives. During the period, she launched a series of events promoting Hong Kong’s green-related services and biomedical sector including the Asia Summit on Global Health. She is also responsible to promote Hong Kong as a two-way global investment hub through strengthening the Council’s deal-making platforms.<br><br>Ms Cheung is a graduate of the Hong Kong University of Science and Technology.</div></div>

Ms Anna Cheung

Convenor

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Hospital Chief Executive</div>The Chinese Medicine Hospital of Hong Kong

<div class="container">
    <div class="mb-4 w-100">
        <div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2026/01/Prof-Bian-Zhaoxiang.jpg" />
        </div>
        <div>
            <div class="speaker-name">Professor BIAN Zhaoxiang</div>
            <div class="speaker-company">Hospital Chief Executive</div>
            <div class="speaker-title">The Chinese Medicine Hospital of Hong Kong</div>
        </div>
    </div>
</div>
<div class="container">
    <div class="speaker-details" style="text-align: justify;">Professor Bian Zhaoxiang is a leading expert in Chinese medicine clinical studies, a respected research scientist in the field of gut dysbiosis, and a relentless advocate for incorporating Chinese medicine into a holistic healthcare system.<br><br> 
Since joining HKBU in 2001, Professor Bian has held various positions, including the Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, Director and Chair Professor of the Clinical Division, Director of the Centre for Chinese Herbal Medicine Drug Development, Director of the Chinese EQUATOR Centre, and Director of the Vincent VC Woo Chinese Medicine Clinical Research Institute.
</div>
</div>

Prof Bian Zhaoxiang

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Senior Executive Director</div>The Hong Kong Association of the Pharmaceutical Industry

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Sabrina_Chan-2.jpg" /></div><div><div class="speaker-name">Ms Sabrina Chan</div><div class="speaker-company">Senior Executive Director</div><div class="speaker-title">The Hong Kong Association of the Pharmaceutical Industry</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Sabrina is the Senior Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI). She is currently member of the High Level Steering Committee on Antimicrobial Resistance, member of Postgraduate Pharmacy Training and Development Committee, the Pharmacy and Poison Board of Hong Kong and member of Wholesales &amp; Retail Task Force under Business Facilitation Advisory Committee, the government of HKSAR. She is also the Chair of the Advisory Board of Pharmacy Education, Department of Pharmacology and Pharmacy, the University of Hong Kong as well as member of Clinical Translational Catalyst Assessment Panel, HK Science and Technology Parks Corporation; member of Steering Committee, Asia Partnership Conference of Pharmaceutical Associations (APAC); member of APEC Biopharmaceutical Working Group on Business Ethics and member of Inter-governmental Organisation, Ethics and Compliance Committee, International Federation of Pharmaceutical Manufacturers Associations (IFPMA). <br /><br />She has been awarded APEC 2020 Lighthouse Award on Business Ethics for Small and Medium Enterprises as the first time a Hong Kong people receives the honour. <br /><br />Sabrina studied Communications in Hong Kong when she began her tertiary education. She holds a graduate degree in International Studies from the University of Sheffield (UK), as well as law degrees from University of Tsinghua (China) and the Chinese University of Hong Kong. <br /><br /><b>About HKAPI</b> <a href="www.hkapi.hk" target="_blank" rel="noopener noreferrer">www.hkapi.hk</a> <br />Formed in 1968, HKAPI has 31 full members, including the world’s top 20 companies engaged in pharmaceutical R&amp;D. Its member companies provide over 70 per cent of prescription medicines in Hong Kong. The Association’s mission is to drive the expedient access to innovative healthcare solutions for the people of Hong Kong and Macau with high ethical standard.</div></div>

Ms Sabrina Chan

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Director,<br />Ecosystem Development</div>Hong Kong-Shenzhen Innovation and Technology Park Limited

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2025/10/Anita-Chau.jpg" /></div><div><div class="speaker-name">Ms Anita Chau</div><div class="speaker-company">Director,<br />Ecosystem Development</div><div class="speaker-title">Hong Kong-Shenzhen Innovation and Technology Park Limited</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Anita is an experienced veteran in the tech industry, currently serving as the Director of Ecosystem Development at Hong Kong-Shenzhen Innovation and Technology Park Limited. Prior to this role, she was the Head of Ecosystem Development at Cyberport. With over 25 years of experience in management and business development, Anita has worked with notable companies such as HK Telecom, IBM, Equant, and Wharf T&amp;T.<br /><br />Anita's expertise lies in driving strategic partnerships through business models that incorporate technology into business ecosystems.She has demonstrated professionalism in strategic leadership, cross-functional resource management, and the delivery of high-quality tech solutions.<br /><br />In addition to her professional endeavours, Anita proactively engages in public services. She had been a committee member of the Information and Communications Technology Industry Training Advisory Committee (ITAC) under the Education Bureau, as well as a committee member of the Innovation and Information Technology Committee under the Occupational Safety and Health Council. Today, she fully supports life science cluster development and is an Honorary Board Member of Hong Kong Medical and Healthcare Device Industries Association. Anita is also a pivotal member of incubation and acceleration programs, as well as an avid mentor for startups.<br /><br />Anita serves as the Co-Chair of the Innovation &amp; Technology Executive Committee of the Hong Kong Women Professionals &amp; Entrepreneurs Association. As an active member of the Rotary Club of Hong Kong South, Anita is also a dedicated contributor to the club’s vocation and community services.<br /><br />Anita is committed to developing the younger generation and promoting the development of the I&amp;T value chain, making Hong Kong a better place to live.</div></div>

Ms Anita Chau

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Director of Smart Living</div>Hong Kong Cyberport Management Company Limited

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Ricky_Choi-2.jpg" /></div><div><div class="speaker-name">Mr Ricky Choi</div><div class="speaker-company">Director of Smart Living</div><div class="speaker-title">Hong Kong Cyberport Management Company Limited</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Ricky Choi is responsible for promoting and driving the development of the Smart Living Cluster, with a particular focus on EdTech, HealthTech &amp; GeronTech, GreenTech, PropTech, SocTech, RetailTech &amp; Smart Mobility across Hong Kong and the region. Ricky aims to create abundant opportunities for younger generations to innovate by partnering with industry partners, associations, and ecosystem stakeholders within the Smart City/Smart Living framework.<br /><br />With over 20 years of experience in the Smart Living and Retail Technology industries, Ricky is a member of the Retail Industry Group Executive Committee (RIG EXCO) of the HK Computer Society (HKCS), where he helps facilitate the launch of startups and pioneers automation solutions for retail industry. Ricky has also actively participated in public services related to education, industrial training, and youth development. Currently, he serves as a member of the Committee on Home-School Co-operation (CHSC), appointed by the Education Bureau of the Government of the HKSAR, and a member of The Electronics and Telecommunications Training Board of the Vocational Training Council (VTC).<br /><br />He holds a BA (Hons) degree in Industrial Design from The Hong Kong Polytechnic University, a Master of Arts degree in Architecture from Kingston University, London, an Executive Master of Business Administration (EMBA) from The Chinese University of Hong Kong, and has completed the Executive Education of Technology &amp; Innovation Management Programme from Haas School of Business, University of California, Berkeley.</div></div>

Mr Ricky Choi

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Principal Assistant Secretary for Health</div>Health Bureau

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Gordon_Chong.jpg" /></div><div><div class="speaker-name">Mr Gordon Chong</div><div class="speaker-company">Principal Assistant Secretary for Health</div><div class="speaker-title">Health Bureau</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Mr Chong oversees policies on prevention and control of communicable and non-communicable diseases. His portfolio also covers regulation of pharmaceutical products, as well as Mainland and international co-operation on health-related issues.</div></div>

Mr Gordon Chong

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Founder & CEO</div>Ryoden Medical Holdings Ltd

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Charles_Hu-2.jpg" /></div><div><div class="speaker-name">Dr Charles Hu</div><div class="speaker-company">Founder &amp; CEO</div><div class="speaker-title">Ryoden Medical Holdings Ltd</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">A translational biomedical engineer with a strong background in business development and investments, Charles’s vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area. He obtained his PhD from Johns Hopkins University, BS from University of California, Berkeley, and his scientific expertise interfaces across biomedical engineering, regenerative medicine, interventional radiology, and materials science. He is also experienced in research commercialization and in MNC pharma product development and medical affairs. He co-founded Incando Therapeutics to bring innovative therapeutic technologies to the clinical stage and targeting difficult to treat diseases including recurrent cancer and neurodegenerative diseases. On the business front, Charles heads Ryoden Medical Holdings where he oversees healthcare venture investments for his family office, advises angel investors and startups, and actively engages in policy discussions in support of biomedical innovations and youth talent development.<br /><br />Charles is an Adjunct Professor of Biomedical Sciences, Industrial Advisor of Biomedical Engineering, Anniversary Steering Committee member, and HK Tech 300 Angel Fund selection panelist at the City University of Hong Kong, vice president of the Hong Kong Biotechnology Organization (HKBIO), Council Advisor to the Asian Fund for Cancer Research, Social Affairs Committee and Technological Innovation Committee member of the Hong Kong Professionals and Senior Executives Association (HKPASEA), and director of several biotech, retail, food &amp; beverage, and real estate businesses. He was awarded the Outstanding Young Entrepreneur Award and Best Sci-Tech Innovation Project in 2023 by the Guangdong-HK-Macao Bay Area Entrepreneurs Union and the Chinese General Chamber of Commerce (“CGCC”) in Hong Kong.</div></div>

Dr Charles Hu

<div class="text-level-caption text-font-bold line-limit-2 mt-1">CEO</div>Tiger Jade Pebble Accelerator

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Emmanuel_Hui-2.jpg" /></div><div><div class="speaker-name">Mr Emmanuel Hui</div><div class="speaker-company">CEO</div><div class="speaker-title">Tiger Jade Pebble Accelerator</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Emmanuel HUI was the founding CEO of Moogene, from zero to IPO (Konex: 322970). Afterwards, he was a Principal managing healthcare exposure at Sagamore, a China-only USD fund of funds with about $800.0m in asset value. He then founded Pentepebble and merged it with Tiger Jade to form the current Pebble Accelerator. HUI currently sits on multiple Boards, including the Hong Kong Hospital Authority Central IRB (Pediatrics), Opharmic, Tonisity China; serves as an advisor to the Hong Kong Life Sciences Society, Thrive Bioscience; and he is a Line Producer for H1Music Limited having worked on various film projects and with the HK Philharmonic Orchestra. <br />HUI graduated from Dartmouth as a Senior Fellow in Chemistry.</div></div>

Mr Emmanuel Hui

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Chief Scientific Officer</div>Hong Kong Center for Neurodegenerative Diseases

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Fanny_Ip-2.jpg" /></div><div><div class="speaker-name">Dr Fanny Ip</div><div class="speaker-company">Chief Scientific Officer</div><div class="speaker-title">Hong Kong Center for Neurodegenerative Diseases</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Dr Fanny Ip is the Chief Scientific Officer of the Hong Kong Center for Neurodegenerative Diseases (HKCeND) and is affiliated with the State Key Laboratory of Molecular Neuroscience in the Division of Life Science of The Hong Kong University of Science and Technology (HKUST). With over 30 years of research experience, Dr Ip is well-versed in molecular neuroscience, medicinal chemistry, drug discovery and development, clinical diagnostics and therapeutics. <br /><br />Dr Ip’s early research focused on understanding the roles of neurotrophic factors in the formation of neuromuscular synapse. She has also investigated the potential beneficial activities of traditional Chinese medicine for the treatment of neurodegenerative and neurological disorders. In recent years, Dr Ip has been orchestrating clinical research studies investigating blood biomarkers associated with Alzheimer's disease for early detection and diagnosis. She has extensive experience in project management for both academic and commercial collaborations and has overseen many government-funded research projects to completion. She has published 70 scientific papers in reputable journals and is a co-inventor of 35 granted patents. Dr Ip has successfully licensed AD therapeutics for clinical development and commercialized laboratory technologies into products and services that serve the community.</div></div>

Dr Fanny Ip 

<div class="text-level-caption text-font-bold line-limit-4 mt-1">Co-Head of China Investment Banking Coverage;<br />Head of Healthcare Asia Pacific,<br />Investment Banking</div>J.P. Morgan Securities (Asia Pacific) Ltd.

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2025/10/David-Lau.jpg" /></div><div><div class="speaker-name">Mr David PW Lau</div><div class="speaker-company">Co-Head of China Investment Banking Coverage;<br />Head of Healthcare Asia Pacific,<br />Investment Banking</div><div class="speaker-title">Hong Kong Center for Neurodegenerative Diseases</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">David PW Lau is Co-Head of China Investment Banking Coverage and Head of APAC Healthcare Investment Banking at J.P. Morgan, responsible for global investment banking strategies for clients in Mainland China and Hong Kong. He joined J.P. Morgan in 1995. David has served various functions during his career at J.P. Morgan, including Equity Capital Markets, Mergers &amp; Acquisitions, China Corporate Finance, and Hong Kong Investment Banking, and worked on a large number of Capital Markets and M&amp;A transactions. David has been serving as a member of Chairmen Pool of Listing Review Committee of the HKEX, a member of the SFC REIT Committee and SFC Process Review Committee, a member of the Economic Advancement Expert Group of the Chief Executive’s Policy Unit (CEPU) of the Hong Kong Government, and a Council member and Audit Committee member of The University of Hong Kong.<br /><br />Prior to joining J.P. Morgan, David worked in Private Equity. David also worked at both the Listing Division of the HKEX and the Hong Kong SFC between 2002 and 2004, and was responsible for IPO vetting and formulating capital market policies. David was a member of the Listing Committee of HKEX from 2017 to 2023, responsible for providing policy advice and taking decisions on listing matters. Between January 2016 to June 2017, David was an Associate Member of the Central Policy Unit of the Hong Kong Government.<br /><br />David graduated from the University of California at Los Angeles majoring in Business Economics.</div></div>

Mr David PW Lau

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Interim Chief Innovation Officer</div>Hong Kong Baptist University

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Terence_Lau-2.jpg" /></div><div><div class="speaker-name">Prof Terence Lau</div><div class="speaker-company">Interim Chief Innovation Officer</div><div class="speaker-title">Hong Kong Baptist University</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Professor Terence Lau has dedicated over 20 years in technology and entrepreneurial ventures, especially in the research &amp; development and commercialisation of innovative products. He will strategically drive high-impact research, the translation and transfer of HKBU’s cutting-edge innovations, as well as policy research in innovation and technology overall. He is also a Senior Advisor to the President and Vice-Chancellor and Honorary Professor of the School of Chinese Medicine.<br /><br />Professor Lau is an accomplished professional with a diverse background in the biotechnology industry and academia. He worked with various stakeholders to promote high-impact research, their translation and application by bridging the gap in technology readiness between academic inventions and real-life applications.<br /><br />Professor Lau holds advisory roles in industry, government, and NGOs, and is the founder of the Food Safety Consortium, a charitable organisation which has become the first WHO/FAO Codex Alimentarius NGO observer from China. He is also the founding Chairman of the Board of the DISH Global Centre for Food Safety &amp; Quality, a non-profit alliance to promote food-related collaborations among EU - Hong Kong / China / Asia Pacific. <br /><br />Professor Lau graduated from The University of Hong Kong with an honours bachelor of science degree in Animal and Plant Biotechnology and subsequently received scientific training at Indiana University (Bloomington) and Stanford University School of Medicine in the US. He also received his Master of Philosophy degree in Biology from the Hong Kong University of Science and Technology, and PhD degree in Physiology from Peking University, China.</div></div>

Prof Terence Lau

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Chief Operating Officer</div>HK Bio-Med Innotech Association

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Ruby_Liao-2.jpg" /></div><div><div class="speaker-name">Ms Ruby Liao</div><div class="speaker-company">Chief Operating Officer</div><div class="speaker-title">HK Bio-Med Innotech Association</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Ms. Liao graduated from The Chinese University of Hong Kong with a master's degree in social policy. In her current capacity, she leads the association's management and operations, spearheads event planning, provides strategic guidance, and ensures successful execution of initiatives. Ms. Liao plays a pivotal role in planning and guiding key events within the life sciences sector, both for the association and government projects. She actively promotes and discusses the growth of Hong Kong's biotechnology industry, focusing on current industry trends and fostering the development of biotechnology talents.<br /><br />Ms. Liao is also responsible for building and coordinating relationships between government entities, universities, research institutions, and biotechnology companies locally and internationally. Her efforts aim to foster positive collaboration among government bodies, industry stakeholders, academic institutions, and research entities in the field of biotechnology. With a wealth of research experience in the institutional and policy realms of Hong Kong's life science industry, Ms. Liao has authored several impactful proposals and industry reports that have influenced policy discussions and practices within the industry, submitted to various government departments.<br /><br />Beyond her professional commitments, Ms. Liao currently serves as a Hong Kong member of the 13th Shanghai Youth Federation and council member of the Hong Kong Young Scientist Association.</div></div>

Ms Ruby Liao

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Chief Manager (Life and Health Technology)</div>Office for Attracting Strategic Enterprises, Financial Secretary’s Office

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Maggie_Lo-2.jpg" /></div><div><div class="speaker-name">Dr Maggie Lo</div><div class="speaker-company">Chief Manager (Life and Health Technology)</div><div class="speaker-title">Office for Attracting Strategic Enterprises, Financial Secretary’s Office</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Dr. Maggie Lo has been the Vice President (Life and Health Technology) at the Office for Attracting Strategic Enterprises (OASES) since December 2022. OASES is the government department responsible for attracting both mainland and international innovation and technology companies to establish or expand their operations in Hong Kong.<br /><br />Before joining the government, Dr. Lo held various roles in universities and health authorities in Hong Kong, the UK, and Canada. Her experience includes clinical research as well as trade and investment promotion, during which she supported numerous companies in establishing or expanding their presence in Hong Kong.<br /><br />Dr. Lo holds a PhD in Psychiatry from the University of Liverpool.</div></div>

Dr Maggie Lo

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Associate Vice-President (Research and Innovation)</div>The University of Hong Kong

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2025/10/Stephanie-KY-Ma.jpg" /></div><div><div class="speaker-name">Prof Stephanie Ma</div><div class="speaker-company">Associate Vice-President (Research and Innovation)</div><div class="speaker-title">The University of Hong Kong</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Professor Ma obtained her B.Sc. (Cell Biology and Genetics) and M.Sc. (Experimental Medicine) degrees from the University of British Columbia. She then graduated with a Ph.D. degree from The University of Hong Kong (HKU) with an outstanding ranking and was awarded the Li Ka Shing Prize for the Best Ph.D. Thesis of that year. Since then, she has been working at HKU where she is currently the Associate Vice-President (Research and Innovation), and the Jimmy and Emily Tang Professor in Molecular Genetics at the School of Biomedical Sciences in the Li Ka Shing Faculty of Medicine. Professor Ma’s research interest is on exploiting stemness as a cancer cell vulnerability. Her team is dedicated to better understand how a more undifferentiated and stemness signature in cancer can contribute to therapy resistance and tumor recurrence. Professor Ma has been listed as a top 1% most-cited scholars by the ISI Essential Science Indicator and top 2% scientists worldwide by Stanford University. She is also the recipient of a number of awards including the more recent 2017 University of British Columbia Alumni Builder Award (Canada), the 2021 Research Grants Council (RGC) Research Fellow Scheme, 2022/23 HKU Outstanding Researcher Award, and the 2023 Croucher Senior Research Fellowship. Professor Ma is a Founding Member of the Hong Kong Young Academy of Sciences in which she currently serves as Vice-President and Co-Chair of their Outreach Committee. She is a member of the Board of Directors at Hong Kong Science and Technology Parks Corporation and a member of the advisory board at the Hong Kong Life Sciences Society.</div></div>

Prof Stephanie Ma

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Vice-President (Research)</div>City University of Hong Kong

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Anderson_Shum-2.jpg" /></div><div><div class="speaker-name">Prof Anderson H.C. Shum</div><div class="speaker-company">Vice-President (Research)</div><div class="speaker-title">City University of Hong Kong</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Professor Anderson Shum Ho-cheung is the Vice-President (Research) of City University of Hong Kong (CityUHK). He also serves as the Chair Professor of Chemical and Biomedical Engineering in the Department of Chemistry and Department of Biomedical Engineering of CityUHK.<br /><br />Professor Shum is an esteemed scholar who received his B.S.E. Degree, summa cum laude, in Chemical Engineering from Princeton University, S.M. and Ph.D. in Applied Physics from Harvard University. His research focuses on emulsions, biomicrofluidics, biomedical engineering and soft matter.<br /><br />Professor Shum has been recognised with numerous international and local scientific awards, including but not limited to: Awardee of RGC Senior Research Fellow Scheme (2024/25), the 15th Guanghua Engineering Science and Technology Prize by Chinese Academy of Engineering (CAE, 2024), Gold Medal and International Special Award in 8th International Invention Innovation Competition in Canada (iCAN, 2023), Gold Medal in 48th International Exhibition of Inventions (Geneva, Switzerland, 2023), the inaugural Hong Kong Engineering Science and Technology Award by Hong Kong Academy of Engineering Sciences (2023), NSFC Excellent Young Scientist Fund (2019).<br /><br />Professor Shum is the first scholar in Hong Kong to be selected as a Global Young Academy Member. He is also the President and founding member of the Hong Kong Young Academy of Sciences, and a non-official member of the Committee on Innovation, Technology and Industry Development in the Innovation, Technology and Industry Bureau of the HKSAR Government.</div></div>

Prof Anderson H.C. Shum

<div class="text-level-caption text-font-bold line-limit-2 mt-1">CEO</div>Vitargent (International) Biotechnology Limited

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Jimmy_Tao-2.jpg" /></div><div><div class="speaker-name">Prof Jimmy Tao</div><div class="speaker-company">CEO</div><div class="speaker-title">Vitargent (International) Biotechnology Limited</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Prof. Jimmy Tao is a serial entrepreneur and an adjunct professor at City University of Hong Kong, where he teaches and mentors students and young professionals who want to start their own businesses with social missions. He has over 20 years of experience in founding, funding, and leading innovative companies in various fields, such as power electronics, molecular biology, Alzheimer’s drug discovery, analytical chemistry, and electric bike mid drive system.<br /><br />He is currently the chairman of Hong Kong Biotechnology &amp; Healthcare Council and the chairman of Hong Kong Startup Council at the Federation of Hong Kong Industries, where he supports and advocates for the development and growth of the local start-up ecosystem and the biotechnology sector. He is also an angel investor in 20 companies and a best-selling author and columnist. He has received multiple awards and recognitions for his inventions and contributions, such as the Technology Pioneers by World Economic Forum, the Grand Prix of the International Exhibition of Inventions of Geneva, and the WIPO medal for inventors. His passion and motivation are to work with innovative technologies and bright minds to make the world a better place.<br /><br />He received his BSc from UMIST and holds a Master of Philosophy degree in Engineering from University of Cambridge. He is also a Clinton Global Initiative Commitment Scholar, AOAC Research Institute Advisory Council Member, Advisor of Our Hong Kong Foundation (OHKF) and selected as 1 of 14 Unreasonable Impact Asia Pacific Program leaders by Barclays.</div></div>

Prof Jimmy Tao

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Regional Chief Executive Officer IHH Healthcare North Asia;</div>Chief Executive Officer<br />Gleneagles Hospital Hong Kong

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Kenneth_Tsang-2.jpg" /></div><div><div class="speaker-name">Dr Kenneth Tsang</div><div class="speaker-company">Regional Chief Executive Officer IHH Healthcare North Asia;</div><div class="speaker-company">Chief Executive Officer</div><div class="speaker-title">Gleneagles Hospital Hong Kong</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Dr Kenneth Tsang provides leadership for Gleneagles Hospital Hong Kong, a multi-specialty tertiary hospital under an international healthcare group IHH Healthcare. Dr Tsang leads the hospital to provide excellent and innovative healthcare services in Hong Kong and at a regional level. Dr Tsang also steers the hospital’s development in the realms of digital health, clinical innovations and clinical research to foster its growth into a leading healthcare provider locally and regionally. <br /><br />Dr Tsang joined Gleneagles Hospital Hong Kong in 2019 as Chief Operating Officer and was appointed as its Chief Executive Officer in 2021.<br /><br />Dr Tsang was appointed as Regional Chief Executive Officer of IHH Healthcare North Asia in 2024. In conjunction with his role as Chairman of IHH China Operations Steering Committee, he plays a pivotal role in advancing IHH’s operations in China towards long-term growth. He also leads Parkway Medical Services (Hong Kong) Limited, a member of IHH Healthcare, which operates Gleneagles Healthcare ambulatory centres and clinics and Parkway Laboratory Services in Hong Kong. <br /><br />Prior to joining Gleneagles, Dr Tsang was with the Hospital Authority in Hong Kong for over 25 years, first as a practising physician in the Department of Medicine in Queen Elizabeth Hospital. In 2009, he took up part-time administrative roles at the Kowloon Central Cluster on top of his clinical duties. During the years between 2012 and 2019, he became a full-time medical administrator at the Hospital Authority Head Office, assuming management roles in various areas including Patient Safety, Strategy &amp; Service Planning, Infection Control and Cluster Services.<br /><br />Dr Tsang is a Fellow of the Hong Kong Academy of Medicine (Community Medicine), a Fellow of the Hong Kong College of Community Medicine and a Fellow of The Royal Australasian College of Medical Administrators. He is also an Honorary Clinical Associate Professor of School of Public Health, Li Ka Shing Faculty of Medicine of The University of Hong Kong.</div></div>

Dr Kenneth Tsang

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Director,<br />Business Development</div>Cornerstone Robotics Limited

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2025/10/Fred-Tung.jpg" /></div><div><div class="speaker-name">Mr Fred Tung</div><div class="speaker-company">Director<br />Business Development</div><div class="speaker-title">Cornerstone Robotics Limited</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Fred Tung is the Chairman of the Hong Kong MedTech Association (HKMTA), where he champions and supports initiatives aimed at strengthening collaboration across the healthcare and medical technology sectors. The association engages a broad network of stakeholders including healthcare professionals, R&amp;D experts, manufacturers, end users, regulatory bodies, academics, and international partners, to promote the development of Hong Kong’s MedTech ecosystem.<br /><br />He is currently a member of the Advisory Committee on Health and Medical Innovation and Development (2025-2027) under the Hong Kong Government Health Bureau. In addition to his industry roles, Fred serves as an advisor to the Biomedical Engineering Program (2025-2028) at The Chinese University of Hong Kong and previously held a similar advisory position at City University of Hong Kong. He is also a co-founder of the Hong Kong Private Hospital Operating Theatre Organization.<br /><br />In 2025, Fred joined Cornerstone Robotics Limited as Director of Business Development. Prior to this, he held various leadership positions at Johnson &amp; Johnson, including General Manager for Hong Kong, where he championed the sustainable business development and growth. He was also part of the North Asia Leadership Team, served as Head of Government Affairs (HK), contributed to the Asia Pacific Government Affairs Leadership Team, and sat on the Board of Directors of Johnson &amp; Johnson (HK) Limited.</div></div>

Mr Fred Tung

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Director of Knowledge Transfer and Entrepreneurship</div>The Hong Kong Polytechnic University

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Kelvin_Wong-2.jpg" /></div><div><div class="speaker-name">Mr. Kelvin Wong</div><div class="speaker-company">Director of Knowledge Transfer and Entrepreneurship</div><div class="speaker-title">The Hong Kong Polytechnic University</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Mr. Kelvin Wong currently serves as the Director of the Knowledge Transfer and Entrepreneurship Office (KTEO) at The Hong Kong Polytechnic University ("PolyU"). With a dedicated focus on advancing knowledge transfer and entrepreneurship, Kelvin oversees various channels, including IP management and commercialization, consultancy services, industrial partnerships, start-up investments, innovation, and entrepreneurship development. Additionally, Kelvin is a Registered Technology Transfer Professional (RTTP) and holds the position of Secretary-General at the International Strategic Technology Alliance (ISTA). Under Kelvin's leadership, PolyU has successfully nurtured over 500 start-ups, including four unicorn companies, and effectively translated research output into tangible impact within both industry and society. <br /><br />Prior to joining the academia, Kelvin had an extensive experience in the consumer products industry spanning over 17 years. He held the position of Group Vice President in a multinational company specialising in service robotics. Kelvin successfully led a significant strategic transformation from OEM to establishing their own brand, making the company the world's second-largest manufacturer of robotic mowers and solidifying its reputation and establishing its own brand in the global market. <br /><br />Furthermore, Kelvin has consistently demonstrated his leadership and professional expertise in the field of innovation. His contributions have resulted in the registration of over 250 patents globally, with more than half of them being invention patents. In addition, he was awarded the second prize of “Wu Men Jun AI Science &amp; Technology” in 2017 and bestowed the Suzhou City Distinguished Inventor Award in 2015. He was appointed as a member of the Jiangsu Province Intellectual Management Standardisation Technological Committee.</div></div>

Mr Kelvin Wong

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Dean of Science and Chair Professor in the Division of Life Science</div>The Hong Kong University of Science and Technology

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2025/10/Wong-Yung-Hou.jpg" /></div><div><div class="speaker-name">Prof Wong Yung Hou</div><div class="speaker-company">Dean of Science and Chair Professor in the Division of Life Science</div><div class="speaker-title">The Hong Kong University of Science and Technology</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Professor Wong is the Dean of Science and Chair Professor of Life Science at The Hong Kong University of Science and Technology (HKUST). He also serves as the Director of the Molecular Neuroscience Center, and as an Associate Director of the Biotechnology Research Institute and the Center for Aging Science at HKUST. <br /><br />
Professor Wong obtained his PhD in Pharmacology from the University of Cambridge and conducted postdoctoral training at the University of California San Francisco. Since joining HKUST, his research has been focused on the delineation of the mechanisms of cell signalling, particularly those involving drug receptors. Professor Wong has integrated his scientific endeavours into drug discovery and development in collaboration with pharmaceutical companies. <br /><br />
As an accomplished researcher, he has published over 220 scientific articles and received a number of awards, including the Croucher Senior Research Fellowship and the Medal of Honor. Over the years, Professor Wong had served as a member of the Medical Council of Hong Kong, the Consumer Council of Hong Kong, and the Research Grants Council of Hong Kong (Biology and Medicine Panel). <br /><br />
He is currently serving on the Sir Edward Youde Memorial Fund Council and the Advisory Board of Hong Kong Life Sciences Society. Professor Wong is also a consultant for The Hong Kong Science and Technology Parks Corporation, multinational companies, and local secondary schools to promote biotechnology.</div></div>

Prof Wong Yung Hou

<div class="text-level-caption text-font-bold line-limit-2 mt-1">Director,<br>Knowledge Transfer Office</div>The Chinese University of Hong Kong

<div class="container"><div class="mb-4 w-100"><div class="speaker-img"><img src="/conference/asgh/wp-content/uploads/sites/36/2024/10/Benny_Zee-2.jpg" /></div><div><div class="speaker-name">Prof. Benny Zee</div><div class="speaker-company">Director,<br>Knowledge Transfer Office</div><div class="speaker-title">The Chinese University of Hong Kong</div></div></div></div><div class="container"><div class="speaker-details" style="text-align: justify;">Prof. Benny Zee is the Director of the Office of Research and Knowledge Transfer Services (ORKTS) 2020-present, Director of the Centre for Clinical Research and Biostatistics (CCRB) and Professor of Jockey Club School of Public Health and Primary Care at the Chinese University of Hong Kong (CUHK) since 2001. In addition, he holds honorary appointments in the Department of Clinical Oncology and the Department of Statistics of CUHK; he was the Chairperson of the Joint CUHK-NTEC Clinical Research Ethics Committee from 2006-2020. <br /><br />Professor Zee obtained his PhD in Biostatistics from the University of Pittsburgh, USA, in 1987. He then joined the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) as a Senior Biostatistician and faculty member in the Department of Community Health and Epidemiology and the Department of Mathematics and Statistics of Queen’s University Canada from 1987 to 2001. He remains an Adjunct Professor at Queen’s University after joining CUHK and actively promotes international academic activities and collaborations. <br /><br />Professor Zee is experienced in multi-centre clinical trials, including statistical methods, data management, and drug and medical device development. He has experience developing efficient data management and “big data analytic” research using advanced computer technology. He also has ample experience working with the industry to design and carry out clinical trials that satisfy both academic interests and industry objectives. He has published more than 307 international peer-reviewed journal articles. He serves on various committees, including advisory committees for drug development and data &amp; safety monitoring committees for international drug trials.<br /><br /><br /><b>MORE INFORMATION: </b><a href="https://www.linkedin.com/in/benny-chung-ying-zee-84a11410?" target="_blank" rel="noopener noreferrer">Linkedin</a> <br /><br /><b>PUBLICATION SUMMARY</b><br />ORCID ID: <a href="https://orcid.org/0000-0002-7238-845X" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0002-7238-845X</a> <br /><br /><table><tbody><tr><th> </th><th>h-index</th><th>Publications</th><th>Citations:</th></tr><tr><td>Scopus</td><td>83</td><td>307</td><td>28889</td></tr><tr><td>ResearchGate</td><td>92</td><td>405</td><td>32950</td></tr><tr><td>Google</td><td>96</td><td>528</td><td>41312</td></tr></tbody></table><br /><a href="https://www.scopus.com/authid/detail.uri?authorId=7006378172" target="_blank" rel="noopener noreferrer">Scopus</a> <a href="https://publons.com/researcher/2119970/benny-chung-ying-zee/metrics/" target="_blank" rel="noopener noreferrer">Publons</a> <a href="https://scholar.google.com.hk/citations?hl=en&amp;user=Ecd1TNYAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" target="_blank" rel="noopener noreferrer">Google Scholars</a> <a href="https://www.researchgate.net/profile/Benny_Zee" target="_blank" rel="noopener noreferrer">ResearchGate</a> <a href="http://orcid.org/0000-0002-7238-845X" target="_blank" rel="noopener noreferrer">Orcid</a> <a href="https://www.scholarmate.com/psnweb/outside/homepage?des3PsnId=dZzcXeRfvMuWbJEOIe8MyQ%3D%3D&amp;psnLanguage=0" target="_blank" rel="noopener noreferrer">ScholarMate</a></div></div>

Prof Benny Zee

Members

About the Summit

Honorary Advisors (2026)

ASGH Brochure

Join ASGH Community